GEMoaB, a biopharmaceutical company focused on next-generation immunotherapies for hard-to-treat cancers, has entered into a research collaboration and license agreement with Intellia, a global leader in the field of genome editing treatments. The companies will conduct joint research to combine GEMoaB’s RevCAR technology platform with Intellia’s genome editing technologies to discover and develop next-generation allogeneic cellular immunotherapies for hard-to-treat cancers and i...